Figure 1.

Results following treatment with a 400‐mg SOF‐based regimen. (A) Pretreatment and posttreatment creatinine levels in patients with baseline eGFR <30 mL/minute/1.73 m² (•) and 2 patients receiving dialysis who improved (▴). There was no statistically significant change in creatinine levels or eGFR after treatment. (B) Pretreatment and posttreatment eGFR in patients with baseline eGFR <30 mL/minute/1.73 m² (•) and 2 patients receiving dialysis who improved ((▴). Two patients with MPGN had improvement in their posttreatment estimated creatinine clearance to >60 mL/minute and 31 mL/minute. There was no statistically significant change in creatinine or eGFR after treatment in patients without cirrhosis (n = 7, solid lines), compensated cirrhosis (n = 1, dotted lines), or decompensated cirrhosis (n = 3, dashed lines). Two patients who were liver transplant recipients with renal failure from hepatorenal syndrome and who were receiving hemodialysis had marked improvement in their posttreatment eGFR to 38 mL/minute/1.73 m² and >60 mL/minute/1.73 m². Both were able to discontinue hemodialysis.